Ebola Vaccines, Drugs Added to U.S. Stockpile

"Today we are prepared to add four Ebola countermeasures to the stockpile, whereas three years ago, very few products were even in early stages of development," BARDA Director Rick Bright, Ph.D., said. "This marks a pivotal moment in U.S. and global preparedness for future public health emergencies from viral hemorrhagic fevers like Ebola."

HHS on Sept. 29 announced the first purchase of vaccines and therapeutic drugs for the Ebola virus by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response. These are first vaccines and drugs for Ebola to receive Project BioShield funding, which supports late-stage development toward licensing and stockpile purchases.

"Today we are prepared to add four Ebola countermeasures to the stockpile, whereas three years ago, very few products were even in early stages of development," BARDA Director Rick Bright, Ph.D., said. "This marks a pivotal moment in U.S. and global preparedness for future public health emergencies from viral hemorrhagic fevers like Ebola. We reached this point at unprecedented speed, and that's a direct result of innovative approaches to product development and to partnering across the U.S. government, other nations, and private industry."

The U.S. Department of Homeland Security considers Ebola a potential bioterrorism threat, as well as a naturally occurring public health threat. Under the agreements announced Sept. 29, BARDA will provide Project BioShield funding for each company to validate its manufacturing processes and undertake the final preparations needed to apply for approval through the U.S. Food and Drug Administration; as that work is completed, BARDA can purchase the vaccines and drugs for potential use in a public health emergency.

The HHS agency could buy up to 1.13 million regimens of vaccine, including a single-dose vaccine from Merck Sharp & Dohme Corp of Whitehouse Station, N.J., and a two-dose vaccine from Janssen Vaccines and Prevention B.V. of Leiden, The Netherlands. BARDA also will buy a therapeutic drug from Mapp Biopharmaceutical, Inc. of San Diego, Calif., and a therapeutic drug from Regeneron Pharmaceuticals, Inc. of Tarrytown, N.Y.

The announcement said Merck Sharp & Dohme Corp's single-shot vaccine would be used to protect people at high risk of exposure to Ebola, and BARDA will provide $39.2 million for late-stage development and purchase. Janssen Vaccines and Prevention B.V.'s vaccine is a two-dose vaccine regimen that would be used to prevent illness in people who have not been exposed to Ebola but could be, such as health care workers and the general public; BARDA will provide $44.7 million for late-stage development and purchase under Project BioShield. And for Mapp Biopharmaceutical, BARDA initially will provide $45.9 million for late-stage development and initial purchase of the therapeutic drug ZMapp™ under Project BioShield.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Analyze Incident Data and Maintain OSHA Compliance

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Industry Safe
comments powered by Disqus